Bradley P. Dixon, MD, Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Pediatric Nephrologist at Children’s Hospital Colorado speaks about the ASH 2021 Abstract – 769 Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145040.htmlBackground:Ravulizumab, a humanized anti-complement C5 monoclonal antibody created by modifying eculizumab to attain a longer half-life, has been approved to treat aHUS in the United States (2019), the European Union (2019), and Japan (2020). The results of the phase 3 studies of ravulizumab in adults and children with…
Author: Editor
Bradley P. Dixon, MD, Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Pediatric Nephrologist at Children ‘s Hospital Colorado speaks about the ASH 2021 Abstract – 769 Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145040.htmlBackground:Ravulizumab, a humanized anti-complement C5 monoclonal antibody created by modifying eculizumab to attain a longer half-life, has been approved to treat aHUS in the United States (2019), the European Union (2019), and Japan (2020). The results of the phase 3 studies of ravulizumab in adults and children…
Abdulraheem Yacoub, MD from the University of Kansas Center for Bioinformatics speaks about the ASH 2021 Abstract – 2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148794.htmlBackground:Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor that improves myelofibrosis patient outcomes dramatically (MF). However, ruxolitinib alone may have an unsatisfactory response in some patients; deeper and longer-lasting responses in these patients could be achieved by combining ruxolitinib with medicines that target other signaling pathways involved in MF development. According to recent phase 2 results, adding the phosphatidylinositol 3 kinase (PI3K)…
Abdulraheem Yacoub, MD from the University of Kansas Center for Bioinformatics speaks about the ASH 2021 Abstract – 2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148794.htmlBackground:Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor that improves myelofibrosis patient outcomes dramatically (MF). However, ruxolitinib alone may have an unsatisfactory response in some patients; deeper and longer-lasting responses in these patients could be achieved by combining ruxolitinib with medicines that target other signaling pathways involved in MF development. According to recent phase 2 results, adding the phosphatidylinositol 3 kinase (PI3K)…
Dr. Haythem Y. Ali is a cancer specialist in Troy, Michigan, and is linked with a number of local hospitals, including Henry Ford Hospital and Henry Ford West Bloomfield Hospital. He graduated from the University of Baghdad College of Medicine and has been practicing medicine for over 20 years. In this video Dr. Ali discusses P3-14-17 Exploring racial disparities in BRCA testing for triple negative breast cancer patients: A real-world data analysis.https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo…
Dr. Haythem Y. Ali is a cancer specialist in Troy, Michigan, and is linked with a number of local hospitals, including Henry Ford Hospital and Henry Ford West Bloomfield Hospital. He graduated from the University of Baghdad College of Medicine and has been practicing medicine for over 20 years. In this video Dr. Ali discusses P3-14-17 Exploring racial disparities in BRCA testing for triple negative breast cancer patients: A real-world data analysis.https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo…
Kirsten Timms, Ph.D., VP Biomarker Discovery at Myriad Genetics Inc speaks about SABCS 2021 Abstract – P5-13-09 Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes.
Kirsten Timms, Ph.D., VP Biomarker Discovery at Myriad Genetics Inc speaks about SABCS 2021 Abstract – P5-13-09 Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes.
Paolo Ghia earned his medical degree from the University of Torino and then completed an internal medicine residency. He earned his PhD studying the formation of normal human B cells at the Basel Institute for Immunology in Basel, Switzerland. He then went to Harvard Medical School’s Dana-Farber Cancer Institute in Boston, where he examined the molecular processes of chronic lymphoproliferative diseases, including follicular lymphoma. He is now a Full Professor of Medical Oncology at Università Vita-Salute San Raffaele and Deputy Chairman of the Division of Experimental Oncology at IRCCS Ospedale San Raffaele in Milano, where he is also Head of…
Paolo Ghia received his MD from the University of Torino, Italy, and received his PhD working at the Basel Institute for Immunology, Switzerland, studying B lymphocyte development. Next, he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly of follicular lymphoma at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.  He is now working in Milano, as Professor of Medical Oncology at the Università Vita-Salute San Raffaele; and Deputy Chairman of the Division of Experimental Oncology, at the affiliated Hospital, where he is Director of the Strategic Research Program on CLL, including a dedicated unit for…
Dr. Jerome Goldschmidt graduated from the University of North Carolina School of Medicine with a bachelor of arts in German and a minor in chemistry. At the University of Rochester/Strong Memorial Hospital in Rochester, New York, he completed his medical oncology fellowship. In this video Dr. Goldschmidt discusses Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting.https://ash.confex.com/ash/2021/webprogram/Paper148057.htmlBACKGROUND:Chemotherapy-induced myelosuppressive hematological adverse events (anemia, neutropenia, and thrombocytopenia) are typical side effects in cancer patients. For patients with advanced stage small cell lung cancer,…
Dr. Jerome Goldschmidt graduated from the University of North Carolina School of Medicine with a bachelor of arts in German and a minor in chemistry. At the University of Rochester/Strong Memorial Hospital in Rochester, New York, he completed his medical oncology fellowship. In this video Dr. Goldschmidt discusses Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting.https://ash.confex.com/ash/2021/webprogram/Paper148057.htmlBACKGROUND:Chemotherapy-induced myelosuppressive hematological adverse events (anemia, neutropenia, and thrombocytopenia) are typical side effects in cancer patients. For patients with advanced stage small cell lung cancer,…
Dr. John Mascarenhas is a member of The Tisch Cancer Institute and a professor of medicine at Mount Sinai’s Icahn School of Medicine. He is also the director of the Center of Excellence for Blood Cancers and Myeloid Disorders. He leads clinical research in the Myeloproliferative Disorders Program and directs the Adult Leukemia Program. Dr. Mascarenhas assesses rationale-based innovative therapeutics for patients with MPNs and AML as a clinical investigator in malignant hematology with a focus on translational research involving myeloproliferative neoplasms (MPNs) and their development to acute myeloid leukemia (AML). In this video Dr. Mascarenhas discusses the Oral ASH…
Professor Guy Young, MD, Director, Hemostasis, and Thrombosis Center at Children’s Hospital Los Angeles, Professor of Pediatrics at the Keck School of Medicine of USC speaks about the ASH 2021 Abstract 4 Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper150273.htmlIntroduction:Hemophilia A and B are rare bleeding disorders defined by inefficient clot formation due to thrombin production impairment caused by FVIII or FIX deficiency, respectively. Fitusiran is an experimental siRNA therapy targeting antithrombin that is delivered subcutaneously (SC) to restore thrombin…
Dr. John Mascarenhas is a member of The Tisch Cancer Institute and a professor of medicine at Mount Sinai’s Icahn School of Medicine. He is also the director of the Center of Excellence for Blood Cancers and Myeloid Disorders. He leads clinical research in the Myeloproliferative Disorders Program and directs the Adult Leukemia Program. Dr. Mascarenhas assesses rationale-based innovative therapeutics for patients with MPNs and AML as a clinical investigator in malignant hematology with a focus on translational research involving myeloproliferative neoplasms (MPNs) and their development to acute myeloid leukemia (AML). In this video Dr. Mascarenhas discusses the Oral ASH…
Professor Guy Young, MD, Director, Hemostasis, and Thrombosis Center at Children’s Hospital Los Angeles, Professor of Pediatrics at the Keck School of Medicine of USC speaks about the ASH 2021 Abstract 4 Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper150273.htmlIntroduction:Hemophilia A and B are rare bleeding disorders defined by inefficient clot formation due to thrombin production impairment caused by FVIII or FIX deficiency, respectively. Fitusiran is an experimental siRNA therapy targeting antithrombin that is delivered subcutaneously (SC) to restore thrombin…
Amy Xu, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation – Oligo-progressive disease. Treating locally more than systemically.
Amy Xu, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation – Oligo-progressive disease. Treating locally more than systemically.
Mikkael A. Sekeres, MD from Sylvester Comprehensive Cancer Center, University of Miami speaks about the ASH 2021 Abstract – 242 Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20–30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146154.htmlBackground:Single-agent hypomethylating agent (HMA) therapy is often used in older patients with higher-risk MDS/CMML or AML with 20–30 percent marrow blasts. The median response duration and survival for these individuals is poor, and many MDS patients progress to secondary AML, which has…
Mikkael A. Sekeres, MD from Sylvester Comprehensive Cancer Center, University of Miami speaks about the ASH 2021 Abstract – 242 Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20–30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146154.htmlBackground:Single-agent hypomethylating agent (HMA) therapy is often used in older patients with higher-risk MDS/CMML or AML with 20–30 percent marrow blasts. The median response duration and survival for these individuals is poor, and many MDS patients progress to secondary AML, which has…
Pedram Razavi, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about SABCS 2021 Presentation – Challenges in early detection – screening and MRD.
Pedram Razavi, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about SABCS 2021 Presentation – Challenges in early detection – screening and MRD.
Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he received his medical degree from Wayne State University School Of Medicine. DMC Hutzel Women’s Hospital is where he works. In this video Dr. Zonder discusses the REGN5458 (BCMAXCD3) Phase 1 Data. https://ash.confex.com/ash/2021/webprogram/Paper144921.html REGN5458 is a bispecific antibody designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells in order to bridge them together and activate T-cells to kill the cancer cells. It is now being evaluated as part of the potentially registrational Phase 2 component…
Steven W. Pipe, MD from the Department of Pediatrics and Pathology, University of Michigan speaks about 972 Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper144508.htmla brief introduction -The adeno-associated virus gene therapy valoctocogene roxaparvovec (AAV5-hFVIII-SQ) delivers a B-domain deleted factor VIII (FVIII) cDNA to hepatocytes. In 134 men with severe hemophilia A (HA), the open-label, single-arm, multicenter phase 3 GENEr8-1 study (NCT03370913) found that valoctocogene roxaparvovec reduced annualized treated bleeding rate (ABR) by 83.8 percent and was superior to…
Steven W. Pipe, MD from the Department of Pediatrics and Pathology, University of Michigan speaks about 972 Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper144508.htmla brief introduction -The adeno-associated virus gene therapy valoctocogene roxaparvovec (AAV5-hFVIII-SQ) delivers a B-domain deleted factor VIII (FVIII) cDNA to hepatocytes. In 134 men with severe hemophilia A (HA), the open-label, single-arm, multicenter phase 3 GENEr8-1 study (NCT03370913) found that valoctocogene roxaparvovec reduced annualized treated bleeding rate (ABR) by 83.8 percent and was superior to…
John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the ASH 2021 Abstract – 1503 A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148931.htmlMyeloproliferative neoplasm (MF) is a life-threatening myeloproliferative tumor. Only the JAKi inhibitors ruxolitinib and fedratinib have been approved by the FDA as treatments for MF. Despite the benefits reported with ruxolitinib in the frontline setting, a high proportion of patients (pts) discontinue treatment (Abdelrahman 2015), and the median overall…
John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the ASH 2021 Abstract – 1503 A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148931.htmlMyeloproliferative neoplasm (MF) is a life-threatening myeloproliferative tumor. Only the JAKi inhibitors ruxolitinib and fedratinib have been approved by the FDA as treatments for MF. Despite the benefits reported with ruxolitinib in the frontline setting, a high proportion of patients (pts) discontinue treatment (Abdelrahman 2015), and the median overall…
Shyamala Maheswaran, Ph.D. from Massachusetts General Hospital speaks about the SABCS Presentation – Single Cell Analysis Of Circulating Tumor Cells.
Shyamala Maheswaran, Ph.D. from Massachusetts General Hospital speaks about the SABCS Presentation – Single Cell Analysis Of Circulating Tumor Cells.
Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84 Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145757.htmlBackground:Multiple myeloma (MM) is a malignancy characterized by terminally differentiated plasma cells that produce high levels of antiapoptotic proteins such as BCLÂÂÂ-2. Venetoclax (Ven), an oral BCL-2 inhibitor that promotes apoptosis in MM cells, showed promise efficacy when coupled with bortezomib and dexamethasone in patients with relapsed/refractory MM (RRMM; Moreau et al. Blood. 2017;130:2392-2400). The…
Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84 Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145757.htmlBackground:Multiple myeloma (MM) is a malignancy characterized by terminally differentiated plasma cells that produce high levels of antiapoptotic proteins such as BCLÂÂÂ-2. Venetoclax (Ven), an oral BCL-2 inhibitor that promotes apoptosis in MM cells, showed promise efficacy when coupled with bortezomib and dexamethasone in patients with relapsed/refractory MM (RRMM; Moreau et al. Blood. 2017;130:2392-2400). The…
Dr. Raymond L. Comenzo is a Tufts Medical Center-affiliated oncologist in Boston, Massachusetts. He graduated from Boston University School of Medicine and has been practicing medicine for almost 20 years. In this video Dr. Comenzo discusses the Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA StudyLink to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper146820.htmlIntroduction: Light chain (AL) amyloidosis is a plasma cell disease in which insoluble amyloid fibrils develop in tissues, causing organ failure and death. The ANDROMEDA trial (NCT03201965) found that adding SC daratumumab to the standard-of-care combination of bortezomib,…
Morie A Gertz, MD, MACP from the Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 2754 Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146076.htmlBackground:Light chain (AL) amyloidosis is a rare, deadly hematologic condition characterized by misfolded AL protein produced by plasma cells, culminating in amyloid deposits in tissues and organs, causing organ malfunction and failure. Birtamimab is an experimental monoclonal antibody that neutralizes circulating soluble amyloid and deposited insoluble amyloid, allowing amyloid deposits to be phagocytized and cleared. The global phase…
Morie A Gertz, MD, MACP from the Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 2754 Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146076.htmlBackground:Light chain (AL) amyloidosis is a rare, deadly hematologic condition characterized by misfolded AL protein produced by plasma cells, culminating in amyloid deposits in tissues and organs, causing organ malfunction and failure. Birtamimab is an experimental monoclonal antibody that neutralizes circulating soluble amyloid and deposited insoluble amyloid, allowing amyloid deposits to be phagocytized and cleared. The global phase…
Dr. Med. Prof. Martin Dreyling, PhD, Department of Medicine III, LMU Hospital speaks about ASH 2021 Abstract – 383 R-High Dose Cytarabine/Dexamethasone (R-HAD) Plus Bortezomib Is Superior to R-HAD Only in Relapsed Mantle Cell Lymphoma: A Randomized Phase 3 Trial of the European MCL Network.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148585.htmlBackground:Relapsed mantle cell lymphoma (MCL) has an aggressive clinical history and only achieves a short-term remission after immunochemotherapy. The addition of high-dose cytarabine to a CHOP-like regimen resulted in significantly longer time to treatment failure (TTF) in younger patients (Hermine et al, Lancet 2016), whereas the addition of bortezomib to a CHOP-like regimen resulted…
Dr. Med. Prof. Martin Dreyling, PhD, Department of Medicine III, LMU Hospital speaks about ASH 2021 Abstract – 383 R-High Dose Cytarabine/Dexamethasone (R-HAD) Plus Bortezomib Is Superior to R-HAD Only in Relapsed Mantle Cell Lymphoma: A Randomized Phase 3 Trial of the European MCL Network.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148585.htmlBackground:Relapsed mantle cell lymphoma (MCL) has an aggressive clinical history and only achieves a short-term remission after immunochemotherapy. The addition of high-dose cytarabine to a CHOP-like regimen resulted in significantly longer time to treatment failure (TTF) in younger patients (Hermine et al, Lancet 2016), whereas the addition of bortezomib to a CHOP-like regimen resulted…
Yael Cohen, MD from Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University speaks about the ASH 2021 Abstract – 3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146072.htmlIntroduction:Patients with progressive multiple myeloma (MM) who are refractory to lenalidomide have numerous therapy choices, however most pts relapse quickly after getting salvage medication. In the phase 1b/2 CARTITUDE-1 research, Cilta-cel, a CAR-T treatment expressing two BCMA-targeting, single-domain antibodies,…
Dr. Raymond L. Comenzo is a Tufts Medical Center-affiliated oncologist in Boston, Massachusetts. He graduated from Boston University School of Medicine and has been practicing medicine for almost 20 years. In this video Dr. Comenzo discusses the Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study.Link to Abstract- https://ash.confex.com/ash/2021/webprogram/Paper146820.htmlIntroduction: Light chain (AL) amyloidosis is a plasma cell disease in which insoluble amyloid fibrils develop in tissues, causing organ failure and death. The ANDROMEDA trial (NCT03201965) found that adding SC daratumumab to the standard-of-care combination of…
Yael Cohen, MD from Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University speaks about the ASH 2021 Abstract – 3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146072.htmlIntroduction:Patients with progressive multiple myeloma (MM) who are refractory to lenalidomide have numerous therapy choices, however most pts relapse quickly after getting salvage medication. In the phase 1b/2 CARTITUDE-1 research, Cilta-cel, a CAR-T treatment expressing two BCMA-targeting, single-domain antibodies,…
Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual appointments at the Alfred Hospital and Monash University, where he does clinical and translational AML research. In this video Professor Wei discusses the Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial. Link to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper147501.htmlBACKGROUND: While many older patients (pts) with AML achieve complete remission (CR) with IC therapy, 80% will recur, and overall survival (OS) is dismal.…
Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual appointments at the Alfred Hospital and Monash University, where he does clinical and translational AML research. In this video Professor Wei discusses the Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial. Link to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper147501.htmlBACKGROUND: While many older patients (pts) with AML achieve complete remission (CR) with IC therapy, 80% will recur, and overall survival (OS) is dismal.…
Elizabeth Lihua Budde, MD, Ph.D. Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope speaks about the ASH 2021 Abstract 127 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145872.htmlBackground:With each course of conventional therapy, FL is linked to more relapses and shorter progression-free intervals. Due to refractory disease, later-line therapies may be less successful. Mosunetuzumab (Mosun) is a bispecific CD20xCD3 antibody (Ab) that drives T lymphocytes…
Elizabeth Lihua Budde, MD, Ph.D. Associate Professor, Division of Lymphoma, Department of Hematology and; Hematopoietic Cell Transplantation at the City of Hope speaks about the ASH 2021 Abstract 127 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145872.htmlBackground:With each course of conventional therapy, FL is linked to more relapses and shorter progression-free intervals. Due to refractory disease, later-line therapies may be less successful. Mosunetuzumab (Mosun) is a bispecific CD20xCD3 antibody (Ab) that drives T lymphocytes…
Dr. Verstovsek is a hematologist-oncologist at MD Anderson and the United Energy Resources, Inc., Professor of Medicine. Dr. Verstovsek is a world-renowned expert in myeloproliferative neoplasms (MPN) and the founder/director of the world’s largest MPN Clinical Research Center. Dr. Verstovsek has received international praise for his role in the development of ground-breaking MPN therapies. He oversaw more than 60 early/advanced phase clinical trials of innovative MPN medications, including ruxolitinib, the only FDA-approved prescription for myelofibrosis (MF) until 2019, and polycythemia vera’s second-line treatment. In this video Dr. Verstovsek discuses the Phase 2 MANIFEST Study evaluating the potential of pelabresib in…
Dr. Verstovsek is a hematologist-oncologist at MD Anderson and the United Energy Resources, Inc., Professor of Medicine. Dr. Verstovsek is a world-renowned expert in myeloproliferative neoplasms (MPN) and the founder/director of the world’s largest MPN Clinical Research Center. Dr. Verstovsek has received international praise for his role in the development of ground-breaking MPN therapies. He oversaw more than 60 early/advanced phase clinical trials of innovative MPN medications, including ruxolitinib, the only FDA-approved prescription for myelofibrosis (MF) until 2019, and polycythemia vera’s second-line treatment. In this video Dr. Verstovsek discuses the Phase 2 MANIFEST Study evaluating the potential of pelabresib in…
Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he received his medical degree from Wayne State University School Of Medicine. DMC Hutzel Women’s Hospital is where he works. In this video Dr. Zonder discusses the REGN5458 (BCMAXCD3) Phase 1 Data. https://ash.confex.com/ash/2021/webprogram/Paper144921.html REGN5458 is a bispecific antibody designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells in order to bridge them together and activate T-cells to kill the cancer cells. It is now being evaluated as part of the potentially registrational Phase 2 component…
Dr. Francesco Passamonti is the Director of the University Hospital of Varese’s Hematology Division. He earned his medical degree from the University of Pavia and went on to become a hematology expert. He served as a hematologist at the Policlinico San Matteo in Pavia, Italy, and as an assistant professor of hematology at the University of Pavia. He serves on the International Working Group on Myeloproliferative Research and Treatment (IWGMRT) Board of Directors, as well as the European LeukemiaNet Work Package 9 for MPN and the GIMEMA Working Party for MPN. He has published over 170 publications on MPN and…
Dr. Francesco Passamonti is the Director of the University Hospital of Varese’s Hematology Division. He earned his medical degree from the University of Pavia and went on to become a hematology expert. He served as a hematologist at the Policlinico San Matteo in Pavia, Italy, and as an assistant professor of hematology at the University of Pavia. He serves on the International Working Group on Myeloproliferative Research and Treatment (IWGMRT) Board of Directors, as well as the European LeukemiaNet Work Package 9 for MPN and the GIMEMA Working Party for MPN. He has published over 170 publications on MPN and…
Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He specializes in coagulation diseases, multiple myeloma, and biosimilars at the advanced subspecialty level. Dr. Rifkin follows the National Comprehensive Cancer Network’s (NCCN) standards and performs evidence-based care. In this video Dr. Rifkin discusses the Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry.Introduction: Treatment resistance is a problem that most MM patients (pts) will face at some point during their illness. Patient outcomes and health-related quality of…
Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He specializes in coagulation diseases, multiple myeloma, and biosimilars at the advanced subspecialty level. Dr. Rifkin follows the National Comprehensive Cancer Network’s (NCCN) standards and performs evidence-based care. In this video Dr. Rifkin discusses the Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry.Introduction: Treatment resistance is a problem that most MM patients (pts) will face at some point during their illness. Patient outcomes and health-related quality of…